Arbutus Biopharma Inc.
- Address
- 701 Veterans Circle
Sponsor Overview
Specializations
Chronic Hepatitis B Research
Arbutus Biopharma Inc. is active in clinical research focused on chronic hepatitis B virus infection, with studies centered on disease control in HBV-suppressed participants and the management of persistent viral infection.
- Chronic HBV infection
- Chronic hepatitis B virus infection
The sponsor’s trial portfolio reflects interest in therapeutic strategies for long-term hepatitis B management and infection-related immune modulation.
Antiviral Therapeutics
Its research activity includes development in antiviral therapy, with attention to agents intended for use in both healthy volunteers and people living with chronic hepatitis B.
- Oral antiviral administration
- Pharmacokinetics and pharmacodynamics
These studies indicate a focus on treatment characteristics relevant to HBV-directed drug development.
Immune-Based Combination Therapy
Arbutus Biopharma also explores combination immunotherapy in chronic HBV infection, including regimens pairing an RNA interference-based approach with an immune checkpoint agent.
- Immunotherapy combinations
- Immune checkpoint modulation
This area highlights interest in therapies that engage both viral suppression and immune response in persistent hepatitis B.
Safety and Tolerability
The sponsor’s trials place emphasis on safety, tolerability, and treatment behavior in human subjects, supporting clinical development in infectious disease therapeutics.
- Safety evaluation
- Tolerability assessment
Research in this domain supports understanding of how candidate therapies perform in hepatitis B-related clinical settings.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-101 in Healthy Volunteers and Patients with Chronic Hepatitis B Virus Infection |  Bulgaria Italy Romania | Not Recruiting |
| Phase 2a Open-Label Study on Safety and Pharmacodynamics of Imdusiran and Durvalumab in Chronic Hepatitis B Patients |  France Poland Romania Spain | Not Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 13 sites across their trial portfolio.
Therapeutic Focus
- 1.Immune System Diseases1 trial322 other sponsors
- 2.Virus Diseases1 trial182 other sponsors
Partnered Research Centres
13 centres- Address
- Piazza Oms 1, 24127 Bergamo
- Address
- Ul. Ul. Jana Dlugosza 4, 51-162 Wroclaw
- Address
- 103 Grande Rue De La Croix Rousse, 69317 Lyon
- Address
- Boulevard De La Chantourne, Cs 10217, La Tronche, 38043 La Tronche
- Address
- Via Francesco Sforza 28, 20122 Milan
- Address
- 100 Boulevard Du General Leclerc, 92110 Clichy
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Arbutus Biopharma Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.